ArticleBMC infectious diseases2025
Metabolomics assays applied to schistosomiasis studies: a scoping review.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolomics in Infectious Diseases and Vaccine Response: Insights into Neglected Tropical and Non-Neglected Pathogens.Infectious disease reports · 2026Review
- Novel Antischistosomal Drug Targets: Identification of Alkaloid Inhibitors of SmTGR via Integrated In Silico Methods.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolomics is an analytical approach utilized to explore the metabolic profiles of biological systems. This process typically involves the application of techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). In the case of schistosomiasis, metabolomics has been employed to identify potential diagnostic biomarkers, examine the host's metabolic response, and explore more effective therapeutic strategies. The objective of this scoping review is to assess the scope and characteristics of metabolomic research on schistosomiasis conducted over the past decade.
methodsTo identify relevant original publications, a systematic search was conducted in the PubMed and Web of Science databases using the following search terms: ("Metabolomics" OR "Metabolomic" OR "Metabonomics" OR "Metabonomic") AND ("Schistosomiasis" OR "Schistosoma"). These terms were applied to the titles and abstracts of the publications, with a focus on the period from January 2014 to December 2024.
resultsThe initial search yielded 48 articles. However, after a thorough evaluation of the abstracts, 14 articles were selected based on the established inclusion criteria. The selection process is visually depicted in the PRISMA flowchart. The majority of the studies included in this review were conducted in China (7 articles) and Brazil (3 articles). Approximately two-thirds of the studies utilized animal models, with serum serving as biofluid in 66% of the studies. The findings of this scoping review suggest that chromatographic techniques coupled with mass spectrometry are predominantly used in metabolomic research on schistosomiasis, accounting for 75% of the studies. The identified metabolites are associated with metabolic pathways related to glycolysis, the TCA cycle, and amino acid metabolism, as well as demonstrating alterations resulting from intestinal dysbiosis observed during the infection. As exemplified by succinate and citrate, which are present in the alterations of energy pathways in Schistosoma mansoni and Schistosoma japonicum species. The serum levels of these metabolites are modified, reflecting the host's metabolic and immunological responses induced by the infections.
conclusionsThese studies successfully elucidated the metabolic pathways and key metabolites involved in schistosomiasis. The findings are significant for the future identification of diagnostic biomarkers and the development of novel antiparasitic agents targeting Schistosoma species. CLINICAL TRIAL: Not Applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.